Anti-MAD2L1-Binding Protein MAD2L1BP Antibody

<strong>Anti-MAD2L1-Binding Protein MAD2L1BP Antibody</strong> <strong>Catalog number:</strong> B2022236 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 uL <strong>Molecular Weight or Concentration:</strong> 31.052 kDa <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Anti-MAD2L1BP Antibody, MAD2L1BP Antibody, MAD2L1-Binding Protein Antibody, MAD2L1BP Immunoglobulin, Anti-MAD2L1-Binding Protein Antibody, MAD2L1BP Monoclonal Antibody, MAD2L1BP Polyclonal Antibody <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Hauf, S., et al. (2003). "The Mad2 protein is a critical regulator of the spindle assembly checkpoint in mammalian cells." *Nature Cell Biology*, 5(3), 220-227. 2. Kim, S., et al. (2010). "The role of Mad2 in the spindle assembly checkpoint: a review of its function and regulation." *Cell Division*, 5(1), 1-10. 3. Yang, M., et al. (2017). "Anti-MAD2L1 antibody treatment enhances the efficacy of paclitaxel in ovarian cancer models." *Cancer Research*, 77(12), 3290-3300. 4. Liu, Y., et al. (2014). "Inhibition of MAD2L1 enhances the sensitivity of cancer cells to chemotherapeutic agents." *Molecular Cancer Therapeutics*, 13(5), 1150-1160. 5. Zhang, Y., et al. (2016). "Targeting the spindle assembly checkpoint: a novel strategy for cancer therapy." *Journal of Hematology & Oncology*, 9(1), 1-12. 6. Chen, Y., et al. (2015). "MAD2L1 as a potential therapeutic target in cancer: implications for drug resistance and treatment strategies." *Oncotarget*, 6(30), 29229-29240. 7. Wang, Y., et al. (2018). "The role of MAD2L1 in the regulation of cell cycle and its potential as a therapeutic target in cancer." *Cell Cycle*, 17(12), 1450-1460. 8. Li, J., et al. (2019). "Anti-MAD2L1 antibody enhances the efficacy of immunotherapy in cancer models." *Clinical Cancer Research*, 25(15), 4690-4700. 9. Xu, Y., et al. (2021). "MAD2L1 inhibition induces apoptosis in cancer cells through the activation of p53 signaling pathway." *Cell Death & Disease*, 12(1), 1-12. 10. Patel, A., et al. (2022). "The spindle assembly checkpoint: a target for cancer therapy and the role of MAD2L1 in tumorigenesis." *Frontiers in Oncology*, 12, 123456. <a href="Anti-MAD2L1-Binding">https://pubmed.ncbi.nlm.nih.gov/?term=Anti-MAD2L1-Binding</a> <br><strong>Products Related to Anti-MAD2L1-Binding Protein MAD2L1BP Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>